Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecBiohitOrionModulight

Latest content

ShowingAll content types

Faron drew down the second tranche of the convertible bond

Analyst Comment 2025-12-12 07:43 by Antti Siltanen
Faron Pharmaceuticals

Nightingale's CFO departs suddenly

Analyst Comment 2025-12-09 06:53 by Antti Luiro, Antti Siltanen
Nightingale Health

New study on the benefits of GastroPanel in guiding treatment

Analyst Comment 2025-12-09 06:52 by Antti Siltanen
Biohit

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Faron presented updated BEXMAB data at the ASH meeting

Analyst Comment 2025-12-09 06:50 by Antti Siltanen
Faron Pharmaceuticals

Bioretec slutför förhandlingar om nedskärningar

Analyst Comment 2025-12-05 07:00 by Antti Siltanen
Bioretec

Orion: den sista Nubeqa-milstolpsbetalningen bekräftades till slut för slutet av året

Analyst Comment 2025-12-04 06:30 by Antti Siltanen
Orion

Herantis: Valuation is attractive again

Research 2025-11-20 11:26 by Antti Siltanen
Herantis Pharma

Bioretec: Building a new beginning

Research 2025-11-14 12:18 by Antti Siltanen
Bioretec

Bioretec Q3’25 snabbkommentar: RemeOs-produktfamiljen kräver ytterligare investeringar i försäljning

Analyst Comment 2025-11-13 08:36 by Antti Siltanen
Bioretec

Biohit: Chilean cancer project raises long-term potential

Research 2025-11-13 09:45 by Antti Siltanen
Biohit
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.